Which CGRP pathway blocking agents are all administered by subcutaneous injection?

Prepare for the Pharmacology IV – Headache Therapeutics Test. Review the therapeutic approaches, tackle multiple-choice questions with explanations, and boost your test-taking confidence. Ace your exam with precision!

Multiple Choice

Which CGRP pathway blocking agents are all administered by subcutaneous injection?

Focus on how these CGRP pathway inhibitors are given. Most CGRP monoclonal antibodies used for migraine prevention are given by subcutaneous injection, allowing at-home dosing for several of them. The exception is one agent that is formulated for intravenous infusion, meaning it’s administered in a clinic or infusion center rather than by needle at home. Among the agents, erenumab, fremanezumab, and galcanezumab are all given subcutaneously. In contrast, eptinezumab is delivered by intravenous infusion. Therefore, the group that is entirely administered by subcutaneous injection consists of erenumab, fremanezumab, and galcanezumab.

Focus on how these CGRP pathway inhibitors are given. Most CGRP monoclonal antibodies used for migraine prevention are given by subcutaneous injection, allowing at-home dosing for several of them. The exception is one agent that is formulated for intravenous infusion, meaning it’s administered in a clinic or infusion center rather than by needle at home.

Among the agents, erenumab, fremanezumab, and galcanezumab are all given subcutaneously. In contrast, eptinezumab is delivered by intravenous infusion. Therefore, the group that is entirely administered by subcutaneous injection consists of erenumab, fremanezumab, and galcanezumab.

More practice questions